Prevention of Recurrent Oral Candidiasis After Dental Procedures

Prophylactic Antifungal Strategy

The Infectious Diseases Society of America recommends chronic suppressive therapy with fluconazole 100 mg three times weekly for patients with recurrent oral candidiasis, as this regimen has been proven effective in preventing oropharyngeal candidiasis in high-risk populations 1, 2, 3
Single-dose fluconazole 200 mg immediately before or after dental procedures may be considered for patients who prefer episodic rather than continuous prophylaxis, though this has less robust evidence than chronic suppressive therapy 1
For patients who cannot tolerate fluconazole, topical antifungals such as clotrimazole troches (10 mg 5 times daily) or nystatin suspension (100,000 U/mL, 4-6 mL 4 times daily) for 7-10 days following each dental procedure can be used 1, 3

Identifying and correcting predisposing conditions, such as immunosuppression, is essential to break the cycle of recurrent infections 1, 2
The Centers for Disease Control and Prevention notes that immunosuppression, including HIV infection, diabetes, malignancy, or corticosteroid use, are major contributors to recurrent oral candidiasis 1
For HIV-infected patients, initiating or optimizing antiretroviral therapy is the single most effective intervention to reduce recurrent candidiasis 1, 2, 3

For mild disease, clotrimazole troches 10 mg 5 times daily for 7-14 days or miconazole mucoadhesive buccal 50-mg tablet once daily for 7-14 days can be used 1, 3, 4
For moderate to severe disease, oral fluconazole 100-200 mg daily for 7-14 days can be used 1, 3, 4
For fluconazole-refractory disease, itraconazole solution 200 mg once daily for up to 28 days or posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily for up to 28 days can be used 1, 3, 4

Do not discontinue prophylactic therapy prematurely once the pattern of recurrence is broken; continue for at least 3-6 months before attempting to taper 1, 3
Do not rely solely on antifungal therapy without addressing underlying risk factors, as this leads to continued relapses 1, 2
Do not use inadequate antifungal doses (less than fluconazole 100 mg) for prophylaxis, as this increases relapse rates and may promote resistance 2, 7

For patients with persistent immunosuppression, chronic suppressive therapy may be required indefinitely, as the benefits of preventing symptomatic disease outweigh the theoretical risk of resistance development 1, 2